Cavalier Investments LLC Has $1.17 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Cavalier Investments LLC raised its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 4.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,785 shares of the biopharmaceutical company’s stock after acquiring an additional 144 shares during the period. Cavalier Investments LLC’s holdings in Madrigal Pharmaceuticals were worth $1,168,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Braidwell LP acquired a new stake in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $39,010,000. Eagle Asset Management Inc. acquired a new stake in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $6,875,000. Intech Investment Management LLC acquired a new stake in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $1,280,000. Vestal Point Capital LP bought a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter worth approximately $6,367,000. Finally, Blueshift Asset Management LLC bought a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter worth approximately $393,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on MDGL. Cantor Fitzgerald reiterated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. HC Wainwright raised their price objective on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. UBS Group raised their price objective on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. B. Riley raised their price objective on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, JMP Securities restated a “market outperform” rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $351.67.

Insider Activity at Madrigal Pharmaceuticals

In other news, CEO William John Sibold sold 1,584 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $531,020.16. Following the completion of the sale, the chief executive officer now directly owns 54,303 shares of the company’s stock, valued at approximately $18,204,537.72. This trade represents a 2.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert E. Waltermire sold 442 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $120,847.22. Following the completion of the sale, the vice president now directly owns 5,058 shares of the company’s stock, valued at $1,382,907.78. This trade represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,690 shares of company stock valued at $2,692,601 in the last three months. Corporate insiders own 22.80% of the company’s stock.

Madrigal Pharmaceuticals Trading Down 3.9 %

MDGL stock opened at $309.49 on Wednesday. The business has a fifty day moving average price of $320.09 and a 200 day moving average price of $282.67. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $189.00 and a fifty-two week high of $368.29. The stock has a market capitalization of $6.75 billion, a price-to-earnings ratio of -12.34 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.